A review of the use of latanoprost for glaucoma since its launch

Digiuni, Maurizio; Fogagnolo, Paolo; Rossetti, Luca

doi:10.1517/14656566.2012.662219

Cited by 71 publications

(45 citation statements)

References 212 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Normal-tension glaucoma (NTG) is the most common type of glaucoma in Japan,3 with a prevalence rate of 3.6% in people over 40 years of age. The ophthalmic solutions 0.005% latanoprost (Lat)4,5 and 0.0015% tafluprost (Taf)6,7 are topical prostaglandin analogs. Both solutions greatly reduce intraocular pressure (IOP) by increasing the uveoscleral outflow as a prostaglandin F receptor agonist 8.…”

Section: Introductionmentioning

confidence: 99%

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Ikeda¹,

Mori²,

Tada³

et al. 2016

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate and compare the intraocular pressure (IOP) reduction efficacy and safety between the ophthalmic solutions 0.005% latanoprost (Lat) and 0.0015% tafluprost (Taf) in Japanese patients with normal-tension glaucoma (NTG).MethodsIn this randomized nonmasked study, we prospectively enrolled 30 Japanese NTG patients who had used Lat monotherapy for more than 4 weeks, and randomly divided them into the following two groups: 1) Lat-to-Taf group (LT group) and 2) Taf-to-Lat group (TL group). At the beginning of the study, both groups were switched from initial Lat to Lat or Taf for 12 weeks, and then switched over to the other drug (crossover) for 12 additional weeks. At 0, 4, 12, 16, and 24 weeks, we evaluated each patient’s IOP, conjunctival injection, and corneal epitheliopathy score, and at 0, 12, and 24 weeks, we evaluated their eyelash changes and pigmentation of the eyelids and irises.ResultsThe mean IOP of the LT group (15 eyes) was 10.5, 10.6, and 11.1 mmHg, at 0, 12, and 24 weeks, respectively, whereas that of the TL group (15 eyes) was 11.7, 11.1, and 10.5 mmHg at 0, 12, and 24 weeks, respectively. No significant differences were found between the two groups and in the intragroup comparisons. Moreover, no significant differences were found between Lat and Taf in regard to the conjunctival injection score and corneal epitheliopathy score. Eyelash changes and eyelid and iris pigmentation were similar in both groups.ConclusionThe findings of this study show that Lat and Taf have equivalent efficacy and safety in Japanese patients with NTG.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma

Ikeda¹,

Mori²,

Tada³

et al. 2016

OPTH

View full text Add to dashboard Cite

show abstract

“…The most common form of glaucoma is primary open angle glaucoma (POAG), and it has the highest prevalence in Africa where it affects 4.20% of the population between 40–80 years of age [1]. Current glaucoma treatments aim to halt glaucoma progression by lowering intraocular pressure (IOP), the buildup of aqueous flow resistance which contributes to RGC damage, but are unable to reverse damage [4,5]. In many cases, despite interventions, glaucomatous damage worsens with time, as ~ 27% of patients with open angle glaucoma may still face blindness in one eye, and 7% in both eyes after years of treatment [6].…”

Section: Introductionmentioning

confidence: 99%

FOXC1 modulates MYOC secretion through regulation of the exocytic proteins RAB3GAP1, RAB3GAP2 and SNAP25

et al. 2017

View full text Add to dashboard Cite

The neurodegenerative disease glaucoma is one of the leading causes of blindness in the world. Glaucoma is characterized by progressive visual field loss caused by retinal ganglion cell (RGC) death. Both surgical glaucoma treatments and medications are available, however, they only halt glaucoma progression and are unable to reverse damage. Furthermore, many patients do not respond well to treatments. It is therefore important to better understand the mechanisms involved in glaucoma pathogenesis. Patients with Axenfeld-Rieger syndrome (ARS) offer important insight into glaucoma progression. ARS patients are at 50% risk of developing early onset glaucoma and respond poorly to treatments, even when surgical treatments are combined with medications. Mutations in the transcription factor FOXC1 cause ARS. Alterations in FOXC1 levels cause ocular malformations and disrupt stress response in ocular tissues, thereby contributing to glaucoma progression. In this study, using biochemical and molecular techniques, we show that FOXC1 regulates the expression of RAB3GAP1, RAB3GAP2 and SNAP25, three genes with central roles in both exocytosis and endocytosis, responsible for extracellular trafficking. FOXC1 positively regulates RAB3GAP1 and RAB3GAP2, while either increase or decrease in FOXC1 levels beyond its normal range results in decreased SNAP25. In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma. The present work reveals that FOXC1 is an important regulator of exocytosis and establishes a new link between FOXC1 and MYOC-associated glaucoma.

show abstract

“…They are known to be highly effective and have little systemic side effects. Latanoprost is an ester prodrug analog of prostaglandin F2α which reduces the intraocular pressure by increasing the uveoscleral outflow2. Latanoprost 0.005% has received the European and the US approval as the first-line drug reducing the intraocular pressure in patients with open angle glaucoma or ocular hypertension.…”

mentioning

confidence: 99%

“…The elevated intraocular pressure is the most important risk factor of glaucoma progression1. According to the World Health Organization and the Glaucoma Foundation, glaucoma is believed to affect between 67 to 105 million people worldwide2. The maintenance therapy with topical anti-glaucoma drug is crucial to prevent a permanent visual loss.…”

mentioning

confidence: 99%

“…Latanoprost 0.005% is the first line drug for glaucoma in Korea as well as in Europe and the United States. The common adverse effects of latanoprost are conjunctival hyperemia, hypertrichosis and hyperpigmentation, but these are only mild and tolerable side effects2. Allergic contact dermatitis due to latanoprost may cause pruritic skin eruptions although it is a very rare side effect.…”

mentioning

confidence: 99%

See 1 more Smart Citation